[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.171.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
July 13, 2011

Fibrate Use in the United States and Canada

JAMA. 2011;306(2):157-159. doi:10.1001/jama.2011.945

To the Editor: Dr Jackevicius and colleagues reported that the use of fibrates has paradoxically increased in the United States “despite published negative results from fibrate trials.”1 The authors used interpretations of the data that precluded clarification of this apparent paradox. Jackevicius et al declared that “[t]he main evidence for clinical benefit comes from placebo-controlled trials with the older fibrates such as . . . clofibrate (which is no longer available due to safety concerns)” and that “[a] subgroup analysis in a post-ACCORD meta-analysis found that fenofibrate use did not reduce coronary events compared with placebo.”

First Page Preview View Large
First page PDF preview
First page PDF preview
×